Clinical Trials Logo

Clinical Trial Summary

Rationale: Currently, for youngsters there is no treatment available that directly targets the core symptoms of autism. EMDR is hypothesized to improve the core symptoms of ASD by reducing the generally high stress levels experienced during social interactions, and increasing the functional connectivity in neuronal networks associated with executive functioning and limbic circuitry.

Objective: The primary objective of the study is to determine if EMDR reduces the core symptoms of ASD and daily experienced stress in youngsters diagnosed with ASD.

Study design: Longitudinal multiple single case studies. Study population: Youngsters aged 12-21 years who are diagnosed with ASD and have a full-scale IQ of 80 or more (N=20).

Intervention: 10 weekly EMDR sessions.

Main study parameters/endpoints: The main endpoint of the study are autism symptoms, which will be assessed using the Social Responsiveness Scale (SRS-A) and the Autism Diagnostic Observation Schedule (ADOS 2). The SRS-A will be administered prior, during and after treatment. The ADOS 2 will be administered prior to treatment and after treatment completion. In addition, we will also administer the Trauma Symptom Investigation Form in Autism Spectrum Disorders (TIF-ASD) questionnaire prior to, during, and after treatment. Furthermore, to answer more fundamental questions concerning the working mechanism of EMDR in ASD, other secondary outcome measures (i.e. PSS-10, AWMA-2) will be included.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants are expected to benefit from treatment. The risks associated with study participation are considered negligible and the burden associated with participation is estimated as low.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03467464
Study type Interventional
Source Karakter Kinder- en Jeugdpsychiatrie
Contact Esther Leuning, Msc
Phone 0031 621902722
Email e.leuning@karakter.com
Status Recruiting
Phase N/A
Start date December 1, 2017
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT03286621 - Development of Eye-tracking Based Markers for Autism in Young Children
Active, not recruiting NCT03693313 - The Effect of CrossFit Kids on Social Skills in Children With Autism Spectrum Disorder (CrossFit KAMP) N/A
Recruiting NCT03206996 - Exposure Therapy for Auditory Sensitivity in Autism N/A
Completed NCT02299700 - Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder N/A
Recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Recruiting NCT03678129 - GABA Pathways in Autism Spectrum Disorder (ASD) N/A
Recruiting NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Not yet recruiting NCT03605368 - VR Intervention to Improve Police Safety N/A
Recruiting NCT02776215 - Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents Phase 1
Recruiting NCT03376373 - Neurotherapy to Promote Emotion Recognition in Autism N/A
Recruiting NCT02791321 - Fragility Assessment in Adults With ADHD and Mental Retardation N/A
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Recruiting NCT02608333 - Efficiency of Early Intervention for Autism Spectrum Disorder N/A
Recruiting NCT02903732 - Autism Registry for French Guiana N/A
Enrolling by invitation NCT02465086 - Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population N/A
Completed NCT02555241 - Emergence of Generative Language N/A
Completed NCT02552147 - Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism Phase 1
Withdrawn NCT01352611 - Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen N/A